Develops pharmaceuticals and women's health products, focusing on reproductive health and biosimilars.
Organon & Co., based in Jersey City, New Jersey, is a prominent healthcare company dedicated to developing and delivering a wide range of health solutions globally. Established in 2020, the company focuses on enhancing patient care through its diverse portfolio of prescription therapies. Organon's commitment spans various therapeutic areas, with a significant emphasis on women's health. Its portfolio includes leading contraception and fertility brands like Nexplanon/Implanon, offering long-acting reversible contraceptive options that empower women's reproductive choices.
Beyond women's health, Organon & Co. also excels in biosimilars and specialty pharmaceuticals. The company's biosimilars segment features innovative products in immunology and oncology, such as Brenzys, Renflexis, Hadlima, Ontruzant, and Aybintio. Additionally, Organon offers a robust lineup of cardiovascular medications for managing cholesterol and hypertension, including well-known brands like Zetia, Vytorin, Cozaar, and Hyzaar.
Furthermore, Organon & Co. is a leader in respiratory health, providing effective treatments for asthma and allergic rhinitis under brands like Singulair, Dulera, and Nasonex. The company also addresses dermatology, bone health, pain management, and urology with products like Diprosone, Fosamax, Arcoxia, Proscar, and Propecia. Through strategic distribution channels, including drug wholesalers, retailers, hospitals, and government agencies, Organon ensures broad access to its innovative therapies, reinforcing its commitment to advancing global healthcare outcomes.